 WATERTOWN, Mass., Aug. 11, 2021 GLOBE NEWSWIRE -- C4 Therapeutics, Inc. C4T Nasdaq: CCC, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration FDA has granted orphan drug designation ODD to CFT7455 for the treatment of multiple myeloma. 